Fairfax – – October 19, 2026 -- Allergy & Asthma Network will hold the 12th annual USAsthma Summit on Nov. 13, 2026, in Phoenix, Arizona, with free registration for both in-person and livestream attendees.

The one-day event targets public health professionals, clinicians, asthma educators, respiratory therapists, patients, caregivers, advocates and community partners. The organizer says policymakers are considering changes that could affect access to asthma care, and the Summit is meant to address those challenges.

Summit runs alongside the ACAAI Annual Scientific Meeting in Phoenix

The event coincides with the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in the same city. That timing creates additional engagement opportunities for attendees, speakers and leaders in allergy, asthma and immunology.

New York – October 19, 2026 -- Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND) will report its third-quarter 2026 financial results on Tuesday, November 3, 2026, before the market opens. The expedition cruise and adventure travel operator will discuss the figures on an audio conference webcast the same morning.

Lindblad schedules 9:00 a.m. ET webcast for analysts and investors

Management will host the webcast at 9:00 a.m. Eastern Time on November 3. Analysts who want to join the Q&A must use the analyst registration to receive a unique passcode. Dial-in access is also available by phone, with numbers listed by country under meeting ID 416185057.

Earnings release will post to the investor relations site on results day

The earnings release will be available in the investor relations section of the company's website. A replay of the conference will be posted there within 48 hours of its completion.

Toronto – October 19, 2026 -- Vector Science and Therapeutics Corp. (TSXV: PAIN) has appointed Angus Jackson, a former investment banker at Outcome Capital, as Managing Director of Corporate Development. He will lead the company's inorganic growth initiatives, including acquisitions, investments and strategic partnerships.

Jackson takes charge of inorganic growth and supports organic expansion

Jackson will lead inorganic growth and assist with organic growth. His remit covers commercial expansion, strategic alliances, business development and selective mergers and acquisitions. He will also work with company leadership to assess opportunities that complement Vector's therapeutic delivery technologies, medical devices and peptide-related offerings.

Boston – October 19, 2026 -- Servier has dosed the first patients in EMBLEM-1, the pivotal Phase 2 cohort of its Phase 1/2 study of Emiltatug Ledadotin (Emi-Le) in aggressive adenoid cystic carcinoma (ACC), a cancer with no FDA-approved systemic treatment.

Emi-Le is an investigational antibody drug conjugate (ADC) directed against B7-H4. The cohort is enrolling under trial identifier NCT05377996.

EMBLEM-1 uses objective response rate per RECIST 1.1 as its primary endpoint

The trial will measure the percentage of patients who achieve a best overall response of confirmed complete response or partial response. It will also evaluate the safety of Emi-Le in ACC.

Beverly, Mass. – October 19, 2026 -- DataOne Software, a Dominion Enterprises company, has added Massachusetts vehicle registration and sales data to its Cross-Sell Reports dealer market intelligence products, bringing coverage to 40 states.

Cross-Sell Reports process 3.8 million monthly transactions from state DMV records

The platform handles an average of more than 3.8 million new and used dealer transactions each month, all sourced from official state DMV records. Each dealer subscription is configured to the dealer's own market area.

Subscribers receive competitive market share analysis by dealership, make and model, plus ZIP code-level heat mapping of buyer activity and emerging markets. Inventory trend analysis covers stocking decisions by segment and season. Interactive dashboards with drill-down reporting require no analytics infrastructure on the dealer side.

New York – October 19, 2026 -- Global MedTech M&A value rose 160% in the first half of 2026 versus the same period of 2025, with total disclosed deal value reaching roughly US$130 billion, the highest level in more than a decade, according to the 20th edition of EY US's Pulse of the MedTech Industry report.

The recovery is narrow. EY found it was driven by a limited number of blockbuster transactions rather than broad-based dealmaking.

Industry revenue reached $325 billion in the first half of 2026, up 7.1%

MedTech generated approximately US$650 billion in revenue in 2025, growth of 11%. First-half 2026 revenue of US$325 billion was 7.1% above the prior-year period. Therapeutic devices led growth, followed by non-imaging diagnostics, imaging, and lab equipment and tools.

Secaucus – October 19, 2026 -- A broader set of lab criteria identified primary aldosteronism (PA) in 26.2% of 60,449 U.S. patients, twice the 13.0% flagged under the Endocrine Society's 2025 guidelines, according to a Quest Diagnostics (NYSE: DGX) study published in the journal Hypertension.

Study compares 2025 guideline cutoffs with a permissive threshold

Researchers from Quest Diagnostics, Mass General Brigham, Harvard Medical School and the University of Texas Southwestern Medical School analyzed deidentified Quest lab results. The 2025 criteria require plasma renin activity (PRA) of 1 ng/mL/h or lower, aldosterone of at least 7.5 ng/dL and an aldosterone-to-renin ratio (ARR) above 15. The permissive criteria keep the PRA limit, set aldosterone above 5 ng/dL and drop the ARR requirement.

The authors describe the 2025 guidelines as "overly restrictive," with cutoffs that capture only the most advanced cases.

Las Vegas – October 19, 2026 -- Nicholas Air Founder and CEO Nicholas Correnti will address OEM part supply disruptions, engine OEM program shortfalls and regulatory bottlenecks in a fireside chat at the 2026 NBAA-BACE on Tuesday, October 20, at 2:15 PM on the Horizon Stage.

The convention runs October 19-22 in Las Vegas, Nevada. The National Business Aviation Association describes it as the largest annual gathering of the business aviation community, drawing flight department leaders and operational experts from around the world.

Correnti puts supply and regulation at the center of operator challenges

Correnti will discuss three pressure points for private aviation operators: disruptions in OEM part supply, shortfalls in engine OEM programs, and what he calls antiquated regulatory bottlenecks. He said the event gives operators a forum to address the challenges they face today.

Chicago – October 19, 2026 -- The HNTB-designed South Conveyance Storm Sewer Project at O'Hare International Airport has won the American Society of Civil Engineers Illinois Section's 2026 Outstanding Civil Engineering Achievement Award in the more than $100 million category, after crews tunneled beneath active runways and taxiways without interrupting airport operations.

HNTB engineered tunnel under live airfield for Chicago Department of Aviation

The project provides stormwater infrastructure to support O'Hare's continued modernization and future development. HNTB served as engineer of record and worked with the Chicago Department of Aviation (CDA) and project partners to develop and implement the tunnel solution beneath active airfield infrastructure.

Bridgewater – – October 19, 2026 -- Insmed (Nasdaq: INSM) has launched BRINSUPRI Tablets 25 mg (brensocatib hydrate) in Japan, making it the first and only approved, commercially available treatment for non-cystic fibrosis bronchiectasis (NCFB) in the country.

Japan's health ministry cleared the once-daily oral tablet in August 2026

The Ministry of Health, Labour, and Welfare approved BRINSUPRI based on results from the Phase 3 ASPEN study. The label covers adults and pediatric patients aged 12 years and older.

Samuele Butera, Insmed's Senior Vice President and General Manager, Global Respiratory, called the launch "a meaningful step forward for the bronchiectasis community." Makoto Nakamura, Senior Vice President and General Manager, Japan, said the company will focus on providing information to healthcare professionals and promoting proper use of the therapy.